Meda acquires a new OTC product line in dental health
Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for treating dental erosion. Dental erosion is a common, growing condition that impacts all ages and for which there is currently no effective treatment. The condition is estimated to affect 15-50% of the population and it is sometimes referred to as the “new caries”.
The EB24 product is based on hydrogen fluoride highly diluted in water. In studies, the product has shown that it is able to penetrate enamel surfaces and form calcium fluoride resulting in an anti-erosive effect. As such, EB24 works as a protective agent against dental erosion.
"EB24 will be an important addition to our OTC product portfolio and an excellent complement to CB12," said Jörg-Thomas Dierks, CEO of Meda AB. "The acquisition enables us to continue to build on our OTC offering and adds to future growth."
The EB24 product is expected to be launched in first half of 2015 as a mouth rinse. Patents valid until 2025 have been approved in Europe and are pending in the US. The purchase price will amount up to 77 MSEK over time and is dependent on various milestones such as launch and approvals. Meda will also pay a low, single-digit percentage on sales.
For further inquiries, please contact:
Paula Treutiger, Investor Relations ph: 46 733-666 599
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.
